Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study

Teraoka, Sharon N; Bernstein, Jonine L; Reiner, Anne S; Haile, Robert W; Bernstein, Leslie; Lynch, Charles F; Malone, Kathleen E; Stovall, Marilyn; Capanu, Marinela; Liang, Xiaolin; Smith, Susan A; Mychaleckyj, Josyf; Hou, Xuanlin; Mellemkjaer, Lene; Boice, John D; Siniard, Ashley; Duggan, David; Thomas, Duncan C

doi:10.1186/bcr3057

Table 2 Risk of contralateral breast cancer associated with single-nucleotide polymorphisms reported in prior breast cancer genome-wide association studies

From: Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study

SNP^a	Gene region	Genotype	Cases (CBC)	Controls (UBC)	Per-allele rate ratio^b (95% CI) trend	Heterozygous rate ratio^b (95% CI)	Homozygous rate ratio^b (95% CI)	Pvalue^c
rs2981582	FGFR2	GG	204	449	1.20 (1.04-1.40)	1.26 (0.99-1.60)	1.45 (1.08-1.95)	0.01
		AG	351	672
		AA	149	268
rs1219648	FGFR2	AA	183	433	1.25 (1.08-1.45)	1.36 (1.07-1.74)	1.55 (1.15-2.08)	0.003
		AG	360	676
		GG	162	281
rs12443621	TOX3	GG	173	350	1.03 (0.89-1.19)	1.03 (0.80-1.32)	1.06 (0.79-1.42)	0.70
	(TNRC9)	AG	355	710
		AA	177	326
rs8051542	TOX3	GG	215	421	0.96 (0.82-1.11)	0.81 (0.64-1.04)	0.94 (0.70-1.27)	0.57
	(TNRC9)	AG	344	709
		AA	144	261
rs3803662	TOX3	CC	306	640	1.16 (0.99-1.36)	1.08 (0.87-1.35)	1.43 (1.01-2.01)	0.06
	(TNRC9)	CT	309	606
		TT	88	143
rs889312	MAP3K1	AA	343	658	0.99 (0.85-1.17)	0.95 (0.76-1.18)	1.02 (0.70-1.47)	0.93
		AC	296	597
		CC	67	131
rs3817198	LSP1	AA	320	650	1.08 (0.93-1.27)	1.12 (0.90-1.40)	1.12 (0.79-1.60)	0.31
		AG	309	600
		GG	76	140
rs2107425	H19	CC	325	673	0.97 (0.83-1.14)	1.01 (0.81-1.25)	0.88 (0.62-1.26)	0.74
		CT	311	569
		TT	67	146
rs13281615	8q24	AA	201	420	1.21 (1.04-1.40)	1.06 (0.83-1.35)	1.49 (1.11-2.01)	0.01
		AG	338	720
		GG	166	250
rs30099	5q11	GG	571	1,125	0.92 (0.72-1.18)	0.99 (0.76-1.30)	0.50 (0.18-1.35)	0.50
		AG	128	244
		AA	8	15
rs4666451	2p24	GG	286	524	0.95 (0.82-1.10)	0.86 (0.68-1.08)	0.96 (0.71-1.31)	0.49
		AG	310	669
		AA	106	197
rs13387042^d	2q35	GG	152	326	1.19 (1.02-1.37)	1.12 (0.86-1.47)	1.39 (1.04-1.85)	0.02
		AG	327	669
		AA	225	391
rs11235127	TMEM135	GG	476	977	1.26 (1.04-1.53)	1.12 (0.88-1.41)	2.29 (1.32-4.00)	0.02
		AG	194	373
		AA	35	39
rs7313833	PTHLH	GG	272	616	1.26 (1.08-1.47)	1.24 (1.00-1.55)	1.65 (1.18-2.31)	0.003
		AG	329	625
		AA	103	139
rs16998733	4q31	GG	556	1,071	0.87 (0.69-1.10)	0.77 (0.59-1.00)	1.48 (0.65-3.37)	0.25
		AG	134	291
		AA	11	21
rs1318703	16p31	AA	240	485	1.40 (0.90-1.20)	1.06 (0.84-1.34)	1.11 (0.82-1.50)	0.63
		AG	327	646
		GG	133	234
rs4331913	5p13	GG	247	454	0.98 (0.84-1.14)	0.94 (0.75-1.19)	0.98 (0.72-1.33)	0.77
		AG	343	700
		AA	116	230
rs4954956	2p21	GG	367	748	1.03 (0.88-1.21)	1.03 (0.83-1.28)	1.06 (0.72-1.57)	0.71
		AG	287	532
		AA	53	109
rs6469633	8q23	TT	383	791	1.05 (0.88-1.25)	1.11 (0.89-1.38)	0.96 (0.62-1.50)	0.58
		TC	278	509
		CC	43	86
rs981782	5p12	AA	243	423	0.90 (0.78-1.05)	0.84 (0.67-1.07)	0.84 (0.62-1.12)	0.18
		AC	334	693
		CC	127	271
rs7696175	4p14	GG	268	457	0.88 (0.76-1.02)	0.89 (0.70-1.11)	0.77 (0.57-1.04)	0.09
		AG	319	663
		AA	118	266

^aSingle-nucleotide polymorphisms (SNPs) selected from among the most significantly associated with breast cancer in the genome-wide association studies by Easton and colleagues [7], Hunter and colleagues [8], and Stacey and colleagues [9] described further in the 'Single-nucleotide polymorphism selection' section of Materials and methods. ^bRate ratio adjusted for age at diagnosis of first primary tumor and counter-matching weight. ^cP value with 1 degree of freedom for the association of per-allele SNP genotype and contralateral breast cancer (CBC) risk. ^dFor rs13387402, A is not the minor allele in this study population. CI, confidence interval; UBC, unilateral breast cancer.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us